Adempas Adverse Event Report 2018

$19.99

This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions

Description

Adempas (riociguat) lowers blood pressure in your lungs, helping your heart pump blood more efficiently. Adempas is used to treat chronic thromboembolic pulmonary hypertension (CTEPH) in people who cannot be treated with surgery, or in people who have undergone surgery but still have symptoms. Riociguat can treat certain symptoms of CTEPH and can improve your ability to exercise. Adempas is also used to treat pulmonary arterial hypertension (PAH). Riociguat can improve your ability to exercise and help prevent PAH from getting worse.
Adempas is available to women only under a special program. You must be registered in the program and understand the risks and benefits of this medicine.https://www.drugs.com/adempas.html

Contact US

484-352-2642

What is an Adverse Event Report?

The FDA Adverse Event Reporting System (FAERS) is a database that contains adverse event reports, medication error reports and product quality complaints resulting in adverse events that were submitted to FDA.